Insurance Dilemma: The Leqembi Debate Shaping Alzheimer’s Treatment Access
The introduction of the first drug approved to slow cognitive decline in Alzheimer’s patients, Leqembi, has ignited debates over insurance coverage. While Medicare has opted to cover most patients, private insurers in certain states are hesitant, citing concerns about its cost and experimental nature. Leqembi’s Breakthrough and Coverage Dilemmas Leqembi, a significant development in Alzheimer’s […]
Insurance Dilemma: The Leqembi Debate Shaping Alzheimer’s Treatment Access Read More »